Leukemia methylation markers and uses thereof

• US 10,829,821 B2
• Filed: 08/03/2018
• Issued: 11/10/2020
• Est. Priority Date: 07/06/2016
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California), Youhealth Oncotech Limited
• Original Assignee: Youhealth Oncotech Limited
• Inventors: Zhang, Kang, Hou, Rui, Zheng, Lianghong
• Primary Examiner(s): Martinell, James
• Application Number:
  US16/054,908
• Publication Number:
  US 20190136327A1
• Time in Patent Office: 830 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/154 Methylation markers

Abstract

Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Claims

1. A method of detecting a methylation pattern of a set of biomarkers in a subject suspected of having acute myeloid leukemia, the method comprising:

(a) processing an extracted genomic DNA with a deaminating agent to generate a genomic DNA sample comprising deaminated nucleotides,

wherein the extracted genomic DNA is obtained from a biological sample from the subject suspected of having acute myeloid leukemia; and

(b) detecting the methylation pattern of the set of biomarkers from the processed extracted genomic DNA by contacting the processed extracted genomic DNA with a set of probes and performing a DNA sequencing analysis to detect the methylation pattern of the set of biomarkers,

wherein the set of biomarkers comprises one or more biomarkers selected from;

cg01336231, cg01413582, cg01509330, cg02264990, cg02329430, cg02858512, cg03297901, cg03556653, cg04596071, cg05038216, cg06034933, cg08098128, cg13066703, cg17757602, cg18869709, cg19966212, cg20300129, cg23193870, cg23680451, and cg25145765, and

wherein the set of probes hybridizes to the one or more biomarkers.

2. The method of claim 1, wherein step (b) comprises detecting the methylation pattern of two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more biomarkers.

3. The method of claim 1, wherein step (b) comprises detecting the methylation pattern of cg01336231, cg01413582, cg01509330, cg02264990, cg02329430, cg02858512, cg03297901, cg03556653, cg04596071, cg05038216, cg06034933, cg08098128, cg13066703, cg17757602, cg18869709, cg19966212, cg20300129, cg23193870, cg23680451, and cg25145765.

4. The method of claim 1, further comprising obtaining a methylation score from the methylation pattern of the one or more biomarkers.

5. The method of claim 4, wherein the methylation score is calculated based on Cox proportional hazards (PH) regression analysis.

6. The method of claim 1, wherein the acute myeloid leukemia is metastatic acute myeloid leukemia.

7. The method of claim 1, wherein each probe from the set of probes is a padlock probe.

8. The method of claim 1, wherein the biological sample comprises a blood sample.

9. The method of claim 1, wherein the biological sample comprises a tissue biopsy sample.

10. The method of claim 1, wherein the biological sample comprises circulating tumor cells.

11. The method of claim 1, wherein the subject is a human.

12. The method of claim 1, wherein the DNA sequencing analysis is a padlock probe-based sequencing method.

13. The method of claim 1, wherein each probe from the set of probes is a droplet digital PCR probe.

14. The method of claim 1, wherein the DNA sequencing analysis is a digital PCR sequencing method.

15. A method of detecting a methylation pattern of a set of biomarkers in a subject suspected having acute lymphoblastic leukemia, the method comprising:

(a) processing an extracted genomic DNA with a deaminating agent to generate a genomic DNA sample comprising deaminated nucleotides, wherein the extracted genomic DNA is obtained from a biological sample from the subject suspected of having acute lymphoblastic leukemia; and

(b) detecting the methylation pattern of the set of biomarkers from the processed extracted genomic DNA by contacting the processed extracted genomic DNA with a set of probes and performing a DNA sequencing analysis to detect the methylation pattern of the set of biomarkers,

wherein the set of biomarkers comprises one or more biomarkers selected from;

cg01628067, cg03001333, cg04984818, cg05145233, cg05304729, cg05956452, cg06261066, cg09157302, cg14608384, cg15289427, cg15608301, cg15707093, cg16266227, cg18869709, cg19470372, cg20686234, cg21913319, cg24720672, cg24747122, cg24983367, cg26584619 and cg27178401, and

wherein the set of probes hybridizes to the one or more biomarkers.

16. The method of claim 15, wherein step (b) comprises detecting the methylation pattern of two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more biomarkers.

17. The method of claim 15, further comprising obtaining a methylation score from the methylation pattern of the one or more biomarkers.

18. The method of claim 15, wherein the acute lymphoblastic leukemia is metastatic acute lymphoblastic leukemia.

19. The method of claim 15, wherein the DNA sequencing analysis is a padlock probe-based sequencing method.

20. The method of claim 15, wherein each probe from the set of probes is a padlock probe.

21. The method of claim 15, wherein each probe from the set of probes is a droplet digital PCR probe.

22. The method of claim 15, wherein the DNA sequencing analysis is a digital PCR sequencing method.